Table 4.

Emerging therapies.

Combination	Registration number	Strategy	Phase
Chemotherapy + Immunotherapy	NCT02486718 NCT02657434 NCT02409342 NCT02367781 NCT02366143	Atezolizumab compared with best supportive care following adjuvant cisplatin-based chemotherapy Atezolizumab in combination with carboplatin or cisplatin + pemetrexed Atezolizumab compared with cisplatin or carboplatin in combination with either pemetrexed or gemcitabine Atezolizumab in combination with carboplatin + nab-paclitaxel Atezolizumab in combination with carboplatin + paclitaxel with or without bevacizumab compared with carboplatin + paclitaxel + bevacizumab	III III III III III
Anti VEGF + Immunotherapy	NCT00790010 NCT05063552	Bevacizumab plus ipilimumab Chemotherapy + cetuximab vs chemotherapy + bevacizumab vs atezolizumab + bevacizumab	I II/III
ACT +/- Immunotherapy	NCT03168438 NCT02992743 NCT02588612 NCT03709706	NY-ESO-1 specific (c259) T cells alone or in combination with pembrolizumab NY-ESO-1c259 T cells Autologous T cells expressing enhanced TCRs specific for NY-ESO-1 Autologous T-Cells expressing enhanced TCRs (T Cell receptors) specific for NY-ESO-1/LAGE-1a alone, or in combination with pembrolizumab	I II I Ib/IIa
Emerging therapies- CAR-T cells	NCT05060796 NCT04153799 NCT03525782 NCT02414269 NCT05693844	CXCR5 Modified EGFR Targeted CAR-T Cells CXCR5 Modified EGFR Targeted CAR-T Cells Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells Anti-MSLN CAR T Cells CD40 Ligand Expressing MSLN-CAR T Cell Treatment	EarIy phase I I I and II I and II I and II
Emerging therapies - Cytokine therapy + Immunotherapy	NCT02748564 NCT04905316	IL-2 in combination with Pembrolizumab Canakinumab (IL-1β inhibitor) With Chemoradiation and Durvalumab	II I and II